Key result
CARMA3 deficiency exacerbates cardiac hypertrophy and fibrosis by promoting myofibroblast activation via STAT1 signaling.
Why the study?
The study was conducted to investigate the impact of CARMA3 on fibroblast phenotypic transformation in hypertrophic cardiomyopathy.
CARMA3 suppresses myofibroblast activation and myocardial fibrosis in pressure overload-induced hypertrophic cardiomyopathy by inhibiting STAT1 phosphorylation.
Answers are grounded in this paper and cite their sources.
Hypothesis-generating for CARMA3-STAT1 as antifibrotic target in pressure-overload states; animal data leave open human translation.
Hypertrophic cardiomyopathy (HCM) is characterized by cardiac hypertrophy and fibrosis. To investigate the impact of CARMA3 on fibroblast phenotypic transformation in hypertrophic cardiomyopathy (HCM), the correlation between CARMA3 expression and fibrosis was analyzed in HCM patients. Cardiac function and fibroblast phenotypic transformation were assessed in wild-type and CARMA3-knockout mice subjected to transverse aortic constriction (TAC) or angiotensin II treatment. Additionally, cardiac fibroblasts were screened using flow cytometry and proteomic analysis to identify potential targets. Significant cardiac functional impairment and fibrosis were observed in CARMA3-knockout mice following TAC or angiotensin II treatment. Primary fibroblasts isolated from these mice exhibited increased myofibroblast differentiation, extracellular collagen production, mitochondrial damage, and macrophage inflammation. Elevated STAT1 expression was identified in cardiac fibroblasts from CARMA3-knockout mice through proteomic analysis. Additionally, STAT1 phosphorylation was regulated by CARMA3, and an interaction between CARMA3 and STAT1 was detected in response to pressure overload. In conclusion, CARMA3 may suppress myofibroblast activation by inhibiting STAT1 phosphorylation, thereby improving myocardial fibrosis in pressure overload-induced HCM.
No takes yet. Share an insight, caveat, or question.
Liu et al. (2025) studied Hypertrophic cardiomyopathy and cardiac fibrosis (n=8). CARMA3 knockout / Fludarabine vs. Wild-type / Vehicle was evaluated on Cardiac function (LVEF, FS) and myocardial fibrosis. CARMA3 deficiency exacerbated pressure overload-induced cardiac hypertrophy and fibrosis by promoting myofibroblast activation via the STAT1 signaling pathway.
Synapse has enriched 10 related papers. Consider them for comparative context: